In this free webinar, gain insights into the complex challenges of conducting clinical trials for developmental and epileptic encephalopathy. Attendees will learn about approaches for data collection across large geographic areas. The featured speaker will discuss the factors to consider when selecting cognitive and behavioral endpoints. The speaker will also share approaches for determining minimally clinically important difference.
TORONTO, Sept. 17, 2024 /PRNewswire-PRWeb/ — Clinical trials in patients with developmental and epileptic encephalopathy (DEE) present considerable challenges for research teams, including the difficulty in identifying patients, the large geographic spread of patients and the need for measurements that can catch even the smallest degree of change in behavior or function.
It becomes a near impossible task to find sites that are in the appropriate geographies and have the level of expertise to administer the scales necessary for signal detection.
One byproduct of these challenges is the difficulty that arises in site selection. It becomes a near impossible task to find sites that are in the appropriate geographies and have the level of expertise to administer the scales necessary for signal detection.
In this webinar, the expert speaker will address these obstacles and share solutions. She will describe approaches to collect data across large geographic areas and in locations that do not have specialized or experienced raters. She will share factors to consider when selecting cognitive and behavioral endpoints for DEE trials, including perspectives from regulatory agencies.
Moreover, she will describe the application of developmental assessments (e.g., Bayley-4) and behavioral scales (e.g., the Vineland-3), along with approaches for determining minimally clinically important difference (MCID) with these measures in DEE populations.
Register for this webinar to gain insights into the complex challenges of conducting clinical trials for developmental and epileptic encephalopathy.
Join Pamela Ventola, PhD, Chief Science Officer, Cogstate, for the live webinar on Thursday, October 3, 2024, at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Developmental & Epileptic Encephalopathy (DEE) Trials: Optimizing Endpoints, Determining MCID, and Enhancing Trial Data Quality.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars and digital content to the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps professionals stay current with industry developments, regulations and jobs. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit https://xtalks.com
For information about hosting a webinar visit https://xtalks.com/why-host-a-webinar/
Media Contact
Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com, https://xtalks.com
View original content to download multimedia:https://www.prweb.com/releases/developmental–epileptic-encephalopathy-dee-trials-optimizing-endpoints-determining-mcid-and-enhancing-trial-data-quality-upcoming-webinar-hosted-by-xtalks-302250641.html
SOURCE Xtalks
